Overview

This trial is active, not recruiting.

Condition pancreatic adenocarcinoma
Treatments novottf-100l, gemcitabine, nab-paclitaxel
Phase phase 1/phase 2
Sponsor NovoCure Ltd.
Start date November 2013
End date December 2016
Trial size 40 participants
Trial identifier NCT01971281, EF-20

Summary

The study is a prospective, double arm, non-randomized, open label pilot trial, designed to study the safety, feasibility and preliminary efficacy of a medical device, the NovoTTF-100L concomitant with gemcitabine or concomitant with gemcitabine plus nab-paclitaxel, for front-line therapy of pancreatic adenocarcinoma. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
novottf-100l TTFields
Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
gemcitabine Gemzar
Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
(Experimental)
Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
novottf-100l TTFields
Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
gemcitabine Gemzar
Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
nab-paclitaxel Abraxane
nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.

Primary Outcomes

Measure
Adverse Events Severity and Frequency
time frame: 1.5 years
Feasibility based on compliance with TTFields therapy
time frame: 1.5 yeras

Secondary Outcomes

Measure
Progression Free Survival
time frame: 1.5 years
Overall Survival
time frame: 1.5 years
1 Year Survival Rate
time frame: 1.5 years
6 Month Progression-Free Survival Rate
time frame: 1.5 years
Overall Response Rate based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
time frame: 1.5 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Diagnosis of unresectable locally advanced or metastatic adenocarcinoma of the pancreas with histologically or cytologically confirmed disease. 2. 18 years of age and older 3. Life expectancy of at least 12 weeks 4. Measureable or assessable disease according to the revised RECIST criteria version 1.1. 5. ECOG (Eastern Cooperative Oncology Group) score 0-1 6. Adequate bone marrow, liver and kidney function: 1. Absolute neutrophil count ≥ 1.5 x 10^9/L 2. Platelet count ≥ 100 x 10^9/L 3. Hemoglobin ≥ 10 g/dL 4. AST and/or ALT ≤ 3 x upper limit of normal range (ULN) or ≤ 5 x ULN if patient has documented liver metastases 5. Bilirubin ≤1.5 x ULN 6. Serum creatinine ≤ 1.5 x ULN 7. Coagulation status: PT and PTT within normal limits or within therapeutic limits for patients receiving anticoagulation. 7. Able to operate the NovoTTF-100L System independently or with the help of a caregiver. 8. No concurrent anti-tumor therapy (beyond gemcitabine or gemcitabine and nab-paclitaxel and TTField therapy as per protocol). 9. No prior chemotherapy or radiation allowed. 10. At least 4 weeks since major surgery. 11. Prior surgery allowed for local disease provided a measurable lesion remains on the baseline CT scan. 12. Signed informed consent form Exclusion Criteria: 1. Known brain metastases or meningeal carcinomatosis. 2. Any other malignancy requiring anti-tumor treatment in the past three years. 3. Significant comorbidity which is expected to affect patient's prognosis or ability to receive the combined therapy: 1. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea). 2. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial. 3. Active infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol therapy. 4. History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements of the study or to provide consent. 4. Implantable electronic medical devices including pacemaker, implantable automatic defibrillator, etc. 5. Known allergies to medical adhesives or hydrogel or nab-paclitaxel. 6. Pregnant or breast feeding. 7. Admitted to an institution by administrative or court order

Additional Information

Official title A Phase II Study of TTFields (150 kHz) Concomitant With Gemcitabine and TTFields Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma
Description PAST PRE CLINICAL AND CLINICAL EXPERIENCE: The effect of the electric fields generated by the NovoTTF-100L device (TTFields, TTF) has demonstrated significant activity in in vitro and in vivo pancreatic adenocarcinoma pre-clinical models both as a single modality treatment, in combination with gemcitabine and in combination with paclitaxel. TTFields therapy has also shown to inhibit metastatic spread of malignant melanoma in in vivo experiment. In a small scale pilot study, patients with stage IIIB- IV non-small cell lung cancer (NSCLC) who had had tumor progression after at least one line of prior chemotherapy received Pemetrexed together with TTFields applied to the chest and upper abdomen until disease progression. Efficacy endpoints were remarkably high compared to historical data for Pemetrexed alone. In a large prospective, randomized trial, in recurrent glioblastoma (GBM). The outcome of subjects treated with TTFields was compared to those treated with an effective best standard of care chemotherapy (including bevacizumab). TTFields treated subjects had comparable overall survival to subjects receiving the best available chemotherapy in the US today. Similar results showing comparability of TTFields to best standard of care (BSC) chemotherapy were seen in all secondary endpoints. Recurrent GBM patients treated with TTFields in this trial experienced fewer side effects in general, significantly fewer treatment related side effects, and significantly lower gastrointestinal, hematological and infectious adverse events compared to controls. The only device-related adverse events seen were a mild to moderate skin irritation beneath the device electrodes. Finally, quality of life measures were better in TTFields treated subjects as a group when compared to subjects receiving effective best standard of care chemotherapy. In a large prospective, randomized trial, in newly diagnosed GBM, TTFields in combination with standard-of-care temozolomide chemotherapy extended both progression-free survival and overall survival compared to temozolomide alone. There was no significant increase in serious adverse events from TTFields in combination with temozolomide versus temozolomide alone. The most common adverse reaction from TTFields treatment was mild to moderate skin irritation. DESCRIPTION OF THE TRIAL: All patients included in this trial are diagnosed with unresectable pancreatic adenocarcinoma. In addition, all patients must meet all eligibility criteria. Eligible patients will be enrolled, baseline tests will be performed and the patients will be treated continuously with the device concomitant with gemcitabine or concomitant with gemcitabine plus nab-paclitaxel until disease progression. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. Electrode array placement will require shaving of the abdomen/back as necessary before and during the treatment. After an initial short visit to the clinic for training and monitoring, patients will be released to continue treatment at home where they can maintain their regular daily routine. During the trial,the patient will need to return once every 4 weeks to the clinic where an examination by a physician and a routine laboratory examinations will be done. These routine visits will continue for as long as the patient's disease is not progressing. During the monthly follow up visits to the clinic patients will be examined physically. Additionally, routine blood tests will be performed. A routine CT of the chest and abdomen will be performed at baseline and every 8 weeks thereafter, until disease progression. After this follow up plan, patients will be contacted once per month by telephone to answer basic questions about their health status. SCIENTIFIC BACKGROUND: Electric fields exert forces on electric charges similar to the way a magnet exerts forces on metallic particles within a magnetic field. These forces cause movement and rotation of electrically charged biological building blocks, much like the alignment of metallic particles seen along the lines of force radiating outwards from a magnet. Electric fields can also cause muscles to twitch and if strong enough may heat tissues. TTFields are alternating electric fields of low intensity. This means that they change their direction repetitively many times a second. Since they change direction very rapidly (150 thousand times a second), they do not cause muscles to twitch, nor do they have any effects on other electrically activated tissues in the body (brain, nerves and heart). Since the intensities of TTFields in the body are very low, they do not cause heating. The breakthrough finding made by Novocure was that finely tuned alternating fields of very low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are multiplying, TTFields cause the building blocks of these cells to move and pile up in such a way that the cells physically explode. In addition, cancer cells also contain miniature building blocks which act as tiny motors in moving essential parts of the cells from place to place. TTFields cause these tiny motors to fall apart since they have a special type of electric charge. As a result of these two effects, cancer tumor growth is slowed and can even reverse after continuous exposure to TTFields. Other cells in the body (normal healthy tissues) are affected much less than cancer cells since they multiply at a much slower rate if at all. In addition TTFields can be directed to a certain part of the body, leaving sensitive areas out of their reach. In conclusion, TTField hold the promise of serving as a brand new cancer treatment with very few side effects and promising affectivity in slowing or reversing this disease.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by NovoCure Ltd..